Drug compounders sue FDA over declaration ending Wegovy shortage
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.
